Triumvirate to treat mucormycosis: Interplay of pH, metal ions and antifungal drugs

[1]  Shuaitao Wang,et al.  Strategies for Zinc Uptake in Pseudomonas aeruginosa at the Host–Pathogen Interface , 2021, Frontiers in Microbiology.

[2]  F. Mohammadi,et al.  A case report of rhino-facial mucormycosis in a non-diabetic patient with COVID-19: a systematic review of literature and current update , 2021, BMC Infectious Diseases.

[3]  O. Matveeva,et al.  The Role of Acidosis in the Pathogenesis of Severe Forms of COVID-19 , 2021, Biology.

[4]  R. Ozaras,et al.  COVID-19-associated mucormycosis: Case report and systematic review , 2021, Travel Medicine and Infectious Disease.

[5]  A. Bhardwaj.  Mucormycosis in COVID-19, host-iron assimilation: Probiotics can be novel therapy , 2021, Indian Journal of Physiology and Pharmacology.

[6]  M. Temsah,et al.  COVID-19 and mucormycosis superinfection: the perfect storm , 2021, Infection.

[7]  M. Bhuiyan,et al.  Mucormycosis or black fungus infection is a new scare in South Asian countries during the COVID‐19 pandemic: Associated risk factors and preventive measures , 2021, Journal of medical virology.

[8]  M. R. Ghadami,et al.  Increased incidence of rhino‐orbital mucormycosis in an educational therapeutic hospital during the COVID‐19 pandemic in western Iran: An observational study , 2021, Mycoses.

[9]  J. Helweg-Larsen,et al.  Surgical management of rhinocerebral mucormycosis: A case series , 2021, JPRAS open.

[10]  S. Lalitha,et al.  COVID-19 associated Rhino-orbital Mucormycosis: a Single Centre Experience of Ten Cases. , 2021, QJM : monthly journal of the Association of Physicians.

[11]  S. Bhadada,et al.  COVID‐19‐associated mucormycosis: An updated systematic review of literature , 2021, Mycoses.

[12]  G. Agrawal,et al.  Rise of the phoenix: Mucormycosis in COVID-19 times , 2021, Indian journal of ophthalmology.

[13]  Z. B. Taha,et al.  WITHDRAWN: D-Dimer and Serum Ferritin as an Independent Risk Factor for Severity in COVID-19 Patients , 2021, Materials Today: Proceedings.

[14]  Daryl A Jones,et al.  Zinc supplementation as an adjunct therapy for COVID‐19: Challenges and opportunities , 2021, British journal of clinical pharmacology.

[15]  A. Alunno,et al.  Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units , 2021, Scientific reports.

[16]  A. Bhalla,et al.  Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature , 2021, Mycopathologia.

[17]  Eliot Shevel.  Conditions Favoring Increased COVID-19 Morbidity and Mortality: Their Common Denominator and its Early Treatment. , 2021, Missouri medicine.

[18]  P. Pandilwar,et al.  Mucormycosis: A rare entity with rising clinical presentation in immunocompromised hosts , 2020, International journal of surgery case reports.

[19]  Zhènglì Shí,et al.  Characteristics of SARS-CoV-2 and COVID-19 , 2020, Nature Reviews Microbiology.

[20]  A. Chakrabarti,et al.  Management of Mucormycosis , 2020, Current Fungal Infection Reports.

[21]  G. Weiss,et al.  Prevalence and Predictive Value of Anemia and Dysregulated Iron Homeostasis in Patients with COVID-19 Infection , 2020, Journal of clinical medicine.

[22]  L. Rink,et al.  The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis , 2020, Frontiers in Immunology.

[23]  Linyong Xu,et al.  Serum ferritin as an independent risk factor for severity in COVID-19 patients , 2020, Journal of Infection.

[24]  Yuichi Kubota,et al.  Potential role of zinc supplementation in prophylaxis and treatment of COVID-19 , 2020, Medical Hypotheses.

[25]  Jian Chen,et al.  COVID‐19 infection may cause ketosis and ketoacidosis , 2020, Diabetes, obesity & metabolism.

[26]  E. Hart,et al.  Pulmonary Mucormycosis: Risk Factors, Radiologic Findings, and Pathologic Correlation. , 2020, Radiographics : a review publication of the Radiological Society of North America, Inc.

[27]  C. Faustino,et al.  Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy , 2020, Pharmaceutics.

[28]  G. Garcia-Effron,et al.  In Vitro Activity of Combinations of Zinc Chelators with Amphotericin B and Posaconazole against Six Mucorales Species , 2019, Antimicrobial Agents and Chemotherapy.

[29]  O. Lortholary,et al.  Recent advances in the understanding and management of mucormycosis , 2018, F1000Research.

[30]  S. Leong,et al.  A meta‐analysis of survival factors in rhino‐orbital‐cerebral mucormycosis—has anything changed in the past 20 years? , 2018, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[31]  D. Kontoyiannis,et al.  Therapy of Mucormycosis , 2018, Journal of fungi.

[32]  M. Hoenigl,et al.  Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy , 2018, Drug design, development and therapy.

[33]  A. Ibrahim,et al.  Challenges in the diagnosis and treatment of mucormycosis. , 2018, Medical mycology.

[34]  A. Ibrahim,et al.  Molecular mechanisms of mucormycosis—The bitter and the sweet , 2017, PLoS pathogens.

[35]  D. Kuessner,et al.  The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK. , 2017, Future microbiology.

[36]  D. Denning,et al.  Global access to antifungal therapy and its variable cost. , 2016, The Journal of antimicrobial chemotherapy.

[37]  C. Fraser,et al.  An integrated genomic and transcriptomic survey of mucormycosis-causing fungi , 2016, Nature Communications.

[38]  J. Latgé,et al.  Administration of Zinc Chelators Improves Survival of Mice Infected with Aspergillus fumigatus both in Monotherapy and in Combination with Caspofungin , 2016, Antimicrobial Agents and Chemotherapy.

[39]  E. Swiatlo,et al.  Breaking the Mold , 2016, The Annals of pharmacotherapy.

[40]  G. Sreenath,et al.  Rhinomaxillary mucormycosis with palatal perforation: a case report. , 2014, Journal of clinical and diagnostic research : JCDR.

[41]  A. Shorr,et al.  Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data , 2014, BMC Infectious Diseases.

[42]  A. Paget-Brown,et al.  Safety of an Alkalinizing Buffer Designed for Inhaled Medications in Humans , 2013, Respiratory Care.

[43]  D. McClain,et al.  Iron and diabetes risk. , 2013, Cell metabolism.

[44]  Duncan W. Wilson,et al.  Zinc Exploitation by Pathogenic Fungi , 2012, PLoS pathogens.

[45]  B. Spellberg,et al.  Pathogenesis of mucormycosis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  B. Spellberg,et al.  Recent advances in the management of mucormycosis: from bench to bedside. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  D. Kontoyiannis,et al.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  P. Borghei,et al.  Rhinocerebral mucormycosis: pathways of spread , 2005, European Archives of Oto-Rhino-Laryngology and Head & Neck.

[49]  A. Çağatay,et al.  Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report , 2001, BMC infectious diseases.

[50]  R. Crichton,et al.  Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. , 1994, Kidney international.

[51]  H. Delcher,et al.  A Mechanism of Susceptibility to Mucormycosis in Diabetic Ketoacidosis Transferrin and Iron Availability , 1982, Diabetes.